Contact Us: Sales@finabio.com

Antibody-Dextran Conjugates

Now Available: A Comprehensive Review of the Uses of Antibody-Dextran Conjugates by Dr. Snapper

This technical paper by presents an overview of the development and applications of antibody dextran conjugates. Fina Biosolutions provides anti-IgD and anti-IgM dextrans (mouse and human) as well as other conjugates. Andrew Lees, Scientific Director of Fina Biosolutions, has been synthesizing antibody-dextran conjugates for over 25 years.  
Download the whitepaper [pdf]

  • Anti-IgD dextran — mouse, human
  • Anti-IgD F(ab’)2 dextran — mouse
  • Anti-IgM dextran — mouse, human
  • Human IgG dextran
  • Streptavidin-dextran

Crosslinking membrane IgD on B cells with unconjugated anti-IgD antibody induces B cell proliferation at µg/ml concentrations. By contrast, anti-IgD dextran induces vigorous B cell proliferation at ng/ml. Furthermore, in contrast to unconjugated anti-IgD, anti-IgD-dex-activated B cells undergo substantial Ig class switching and differentiation into Ig-secreting cells in the presence of various second signals, including cytokines and Toll-like receptor ligands. Thus, Anti-IgD-dex is an efficient and potent polyclonal B cell activator for studying a wide range of B cell functions.

Fina Biosolutions provides anti-IgD and anti-IgM dextran conjugates, targeting mouse and human.

Streptavidin-dextran can be used to prepare multivalent polymer conjugates using a biotinylated species (i.e., antibody, TCR, antigen, etc.)

References


dextran

 

 

Figure: Uptake of 3H thymidine as a market of B cell activation

 

 


Pricing

Bulk and custom quotes on request. For Pricing, please contact: Sales@finabio.com

Antibody-Dextran Conjugates

Name Concentration Product No. Size Price
Anti-IgD dextran (mouse) 100 ug/ml FinaBio #0001 10 ug $300
Anti-IgD dextran (human) 100 ug/ml FinaBio #0002 10 ug $300
Anti-IgM dextran (mouse) 100 ug/ml FinaBio #0003 10 ug $300
Anti-IgM dextran (human) 100 ug/ml FinaBio #0004 10 ug $300
Human IgG dextran 100 ug/ml FinaBio #0005 10 ug $300
Anti-IgD (Fab2) dextran (mouse) 100 ug/ml FinaBio #0006 10 ug $500
Streptavidin-dextran 100 ug/ml FinaBio #0101 10 ug $300
Custom dextran conjugates 100 ug/ml FinaBio #1000 10 ug Inquire

Form & Use

Liquid. Sterile filtered at 100µg/mL in PBS. No preservatives. Store at -80°C.
Recommended concentration for flow cytometry is 50-200ng per 1 million cells (100ul).

Safety & Handling

Non-toxic. Avoid contact with skin and eyes. Product may be discarded down drain. Product is intended for research purposes only.


References

  1. Brunswick et al. J. Immunol. 140:3364, 1988. Picogram quantities of anti-Ig antibodies coupled to dextran induce B cell proliferation.
  2. Pecanha et al. J. Immunol. 146:833, 1991. Dextran-conjugated anti-Ig antibodies as a model for T cell-independent type 2 antigen-mediated stimulation of Ig secretion in vitro. I. Lymphokine dependence.
  3. Brunswick et al. J. Immunol. 149:2249, 1992. Comparison of tyrosine kinase activation by mitogenic and nonmitogenic anti-IgD antibodies.
  4. Snapper and Mond. J Immunol. 157:2229, 1996 A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens.
  5. Cho and Conrad. Int. Immunol. 9:239, 1997. A new multivalent B cell activation model–anti-IgD bound to Fc gamma RI: properties and comparison with CD40L-mediated activation.
  6. Kaminski & Stravenzer. Eur J Immunol. 37:240, 2007. Stimuli that enhance IgA class switching increase histone 3 acetylation at S alpha, but poorly stimulate sequential switching from IgG2b.
  7. Foster et al. Clin Vaccine Immunol 17:1104, 2010. Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal

News

  • About FinaBio
    Whitepaper
    Characterization of Fina Biosolutions’ Amino-Dextran
  • About FinaBio

Address

9430 Key West Ave., Suite 200
Rockville, MD 20850
877-346-2246 (877-FinaBio)
301-633-0464 (Andrew Lees, Scientific Director)
Finabio.net
ALees@FinaBio.com

About Us

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.